Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company pioneering the development of first-in-class muscle activators and next-in-class muscle inhibitors. We focus on treating debilitating diseases where muscle performance is compromised, primarily within the cardiovascular therapeutic area. Our innovative approach to muscle biology and the mechanics of muscle performance is driving the development of small molecule drug candidates to improve myocardial muscle function and contractility. Aficamten, our leading drug candidate, is currently making a significant impact in the treatment of hypertrophic cardiomyopathy. Our team utilizes a robust technology stack that includes WordPress, Amazon web services for hosting, and various tools like Google Tag Manager for analytics and Font Awesome for design. We value collaboration and a data-driven approach, ensuring our engineering practices are efficient and effective. Our mission is to improve patients' lives, which is reflected in our commitment to rigorous scientific thinking, integrity, and ethical practices. We're a values-driven company that encourages teamwork, innovation and puts patients at the heart of everything we do. Cytokinetics is a publicly traded company (NASDAQ: CYTK) with 251-500 employees. We boast a strong funding history and are actively expanding our global reach, with opportunities for both in-office and remote work across multiple departments and functions. We encourage individuals passionate about making a difference in the lives of patients with cardiovascular diseases to explore our career opportunities. We champion diversity and inclusion and are an equal opportunity employer.